Which is a better target for AD immunotherapy, Aβ or Tau?

Zane Martin-Jones, Cristian Lasagna Reeves

Research output: Contribution to journalLetter

1 Citation (Scopus)
Original languageEnglish (US)
Pages (from-to)111-112
Number of pages2
JournalAlzheimer Disease and Associated Disorders
Volume22
Issue number2
DOIs
StatePublished - Apr 2008
Externally publishedYes

Fingerprint

tau Proteins
Amyloid beta-Peptides
Immunotherapy
Alzheimer Disease
Vaccines
Brain

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Psychiatry and Mental health
  • Neuroscience(all)
  • Gerontology
  • Clinical Psychology

Cite this

Which is a better target for AD immunotherapy, Aβ or Tau? / Martin-Jones, Zane; Lasagna Reeves, Cristian.

In: Alzheimer Disease and Associated Disorders, Vol. 22, No. 2, 04.2008, p. 111-112.

Research output: Contribution to journalLetter

@article{c43c0133b87b489d95760587255bab6b,
title = "Which is a better target for AD immunotherapy, Aβ or Tau?",
author = "Zane Martin-Jones and {Lasagna Reeves}, Cristian",
year = "2008",
month = "4",
doi = "10.1097/WAD.0b013e3181641355",
language = "English (US)",
volume = "22",
pages = "111--112",
journal = "Alzheimer Disease and Associated Disorders",
issn = "0893-0341",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Which is a better target for AD immunotherapy, Aβ or Tau?

AU - Martin-Jones, Zane

AU - Lasagna Reeves, Cristian

PY - 2008/4

Y1 - 2008/4

UR - http://www.scopus.com/inward/record.url?scp=46249106592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=46249106592&partnerID=8YFLogxK

U2 - 10.1097/WAD.0b013e3181641355

DO - 10.1097/WAD.0b013e3181641355

M3 - Letter

VL - 22

SP - 111

EP - 112

JO - Alzheimer Disease and Associated Disorders

JF - Alzheimer Disease and Associated Disorders

SN - 0893-0341

IS - 2

ER -